Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SERAFA-1 camizestrant + ribociclib in first-line ER-positive, HER2-negative advanced breast cancer
2025-523444-12-00Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, open-label, single-arm trial of camizestrant and ribociclib in breast cancer, sponsored by AstraZeneca. Primary endpoint: Time to next treatment event-free rate at 2 years. Started Aug 2026; status: completed.
02
Drugs
camizestrantribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2025-523444-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523444-12-00.